AVE

AVECHO FPO [AVE]
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Healthcare · ASX Small Cap
$0.0210 -4.6%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 3 consecutive scansFirst seen: 2026-03-05
Get alerts when AVE triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track AVE — Free

Active Signals

Bullish Signals

  • Drifting lower — down 8.7% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Trading above the 200-day average — the long-term trend is on your side
  • Adequate cash runway (7 quarters)
  • Very high P/S ratio (104.8x)
  • Revenue in sharp decline (-89%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 300% over the past year (excluding last month)
  • Excellent risk-adjusted returns — Sharpe of 1.9 means strong gains without wild swings
  • The bigger volume days are the up days — volume-weighted momentum is positive (12.74%/day)
  • Low-priced stock risk ($0.020)
  • RBA hiking (-3pts)

Risk Signals

  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -89% — the top line is shrinking
Ask Scout AI about AVE
"What's driving AVE today?" "How does AVE compare to peers?" "Key risks for AVE?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

HIGH Avecho enters final stage of Phase III insomnia trial
NONE Notification regarding unquoted securities - AVE
NONE Appendix 4D and Half-year Financial Report
NONE Avecho strengthens BD capability with senior appointment

Recent ASX Announcements

2026-08-30 Avecho enters final stage of Phase III insomnia trial PRICE SENSITIVE
2026-08-27 Notification regarding unquoted securities - AVE
2026-08-25 Appendix 4D and Half-year Financial Report PRICE SENSITIVE
2026-08-23 Avecho strengthens BD capability with senior appointment
2026-08-12 Small Holding Share Sale Facility Completion

Key Metrics

$77.3M
Market Cap
3.9M
Avg Volume
1.0x
Vol Ratio
$0.01 — $0.03
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-268.2%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 63%
LLeader vs LaggardpassRS: 46
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:AVE vs REGAVE vs CANAVE vs BIT
Scout Pro — Deeper Analysis for AVE
Try Pro free for 30 days
Share this analysis

Track AVE and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required